Mydocalm (Tolperisone Hydrochloride)

Tolperisone acts centrally by antagonising spinal reflex pathways. It blocks voltage‑gated sodium channels in the central nervous system, which dampens the transmission of excitatory impulses that maintain muscle hypertonicity. This results in a reduction of involuntary muscle contraction and overall muscle tone without directly affecting the neuromuscular junction.

The appropriate dose of Mydocalm is determined by the prescribing clinician based on the individual’s medical condition, severity of symptoms, and response to therapy. Dosage may be adjusted during treatment, and patients should follow the prescriber’s instructions and the product label. No specific regimen is provided here.

Safety data for tolperisone hydrochloride in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Healthcare providers should weigh potential benefits against possible risks before prescribing to pregnant or nursing women, and alternative therapies may be considered when appropriate.

To place an order, submit an enquiry on the Mydocalm product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with other centrally acting muscle relaxants such as baclofen or tizanidine, tolperisone has a distinct mechanism that primarily blocks sodium channels rather than enhancing GABAergic inhibition. This may result in a different side‑effect profile, with less sedation for some patients, though individual response varies and choice of therapy should be guided by clinical judgment.

Mydocalm should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging to protect them from moisture and light. Do not store in bathrooms or near heat sources, and keep out of reach of children. No refrigeration is required for this oral formulation.

Mydocalm is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless otherwise directed by a healthcare professional. Administration can be with or without food, but consistency with meals may help reduce gastrointestinal discomfort. Patients should follow the dosing schedule prescribed by their clinician.

Although uncommon, serious adverse reactions can include severe skin reactions such as Stevens‑Johnson syndrome, blood disorders like agranulocytosis, significant liver enzyme elevations indicating hepatic dysfunction, and anaphylactic‑type hypersensitivity. Patients should seek immediate medical attention if they notice rash, fever, jaundice, unexplained bruising, or difficulty breathing while taking Mydocalm.

Mydocalm is contraindicated in individuals with known hypersensitivity to tolperisone hydrochloride or any excipients in the tablet. Caution is advised for patients with severe hepatic or renal impairment, uncontrolled hypotension, and those concurrently using other potent central nervous system depressants. Pregnant or breastfeeding women should only use it when clearly indicated by a physician. Children and adolescents are generally not recommended unless specifically prescribed.